{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T08:22:21Z","timestamp":1791793341954,"version":"4.3.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012533","name":"Minia University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.tox.2021.153042","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T06:39:03Z","timestamp":1637131143000},"page":"153042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Cardioprotective effects of bosentan in 5-fluorouracil-induced cardiotoxicity"],"prefix":"10.1016","volume":"465","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6211-9558","authenticated-orcid":false,"given":"Marwa M.M.","family":"Refaie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seham A.","family":"Abdel-Gaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Awad Abd El","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Mohamed Naguib Abdel","family":"Hafez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanaa Mohamed","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tox.2021.153042_bib0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.17305\/bjbms.2013.2358","article-title":"Electrophysiological effects of bosentan in rats with induced cerebral ischemia-reperfusion","volume":"13","author":"Akgun","year":"2013","journal-title":"Bosn. J. Basic Med. Sci."},{"issue":"February 10","key":"10.1016\/j.tox.2021.153042_bib0010","article-title":"Paeonol attenuates methotrexate-induced cardiac toxicity in rats by inhibiting oxidative stress and suppressing TLR4-Induced NF-kappaB inflammatory pathway","volume":"2020","author":"Al-Taher","year":"2020","journal-title":"Mediators Inflamm."},{"issue":"4","key":"10.1016\/j.tox.2021.153042_bib0015","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1159\/000489210","article-title":"Camel milk ameliorates 5-fluorouracil-induced renal injury in rats: targeting MAPKs, NF-\u03baB and PI3K\/Akt\/eNOS pathways","volume":"46","author":"Arab","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"21","key":"10.1016\/j.tox.2021.153042_bib0020","doi-asserted-by":"crossref","first-page":"10428","DOI":"10.1158\/0008-5472.CAN-07-1344","article-title":"The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy","volume":"67","author":"Bien","year":"2007","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.tox.2021.153042_bib0025","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s40618-015-0282-y","article-title":"The lung endothelin system: a potent therapeutic target with bosentan for the amelioration of lung alterations in a rat model of diabetes mellitus","volume":"38","author":"Cayir","year":"2015","journal-title":"J. Endocrinol. Invest."},{"issue":"7","key":"10.1016\/j.tox.2021.153042_bib0030","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.healun.2011.03.010","article-title":"Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension","volume":"30","author":"Choudhary","year":"2011","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.tox.2021.153042_bib0035","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/sj.bjc.6600967","article-title":"Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity","volume":"88","author":"Cianci","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tox.2021.153042_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.02.002","article-title":"Fluoropyrimidine-induced cardiotoxicity","volume":"124","author":"Depetris","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.tox.2021.153042_bib0045","doi-asserted-by":"crossref","first-page":"e924446","DOI":"10.12659\/AJCR.924446","article-title":"5-fluorouracil rechallenge after cardiotoxicity","volume":"21","author":"Desai","year":"2020","journal-title":"Am. J. Case Rep."},{"issue":"1","key":"10.1016\/j.tox.2021.153042_bib0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/fca.10.114","article-title":"Bosentan for the treatment of adult pulmonary hypertension","volume":"7","author":"Dwyer","year":"2011","journal-title":"Future Cardiol."},{"issue":"11","key":"10.1016\/j.tox.2021.153042_bib0055","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/clc.4960231128","article-title":"Bosentan and the endothelin system in congestive heart failure","volume":"23","author":"Ellahham","year":"2000","journal-title":"Clin. Cardiol."},{"issue":"824","key":"10.1016\/j.tox.2021.153042_bib0060","article-title":"Endothelin receptor antagonists: status quo and future perspectives for targeted therapy","volume":"9","author":"Enevoldsen","year":"2020","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.tox.2021.153042_bib0065","first-page":"333","article-title":"Comparison of the efficacy of sildenafil alone versus sildenafil plus bosentan in newborns with persistent pulmonary hypertension","volume":"30","author":"Fatima","year":"2018","journal-title":"J. Ayub Med. Coll. Abbottabad"},{"issue":"2","key":"10.1016\/j.tox.2021.153042_bib0070","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10620-008-0366-z","article-title":"Synergistic growth inhibitory effects of the dual endothelin-1 receptor antagonist bosentan on pancreatic stellate and cancer cells","volume":"54","author":"Fitzner","year":"2009","journal-title":"Dig. Dis. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.tox.2021.153042_bib0075","doi-asserted-by":"crossref","first-page":"S354","DOI":"10.1097\/01.fjc.0000166304.40937.0b","article-title":"YM598, an orally active ET(A) receptor antagonist, ameliorates the progression of cardiopulmonary changes and both-side heart failure in rats with cor pulmonale and myocardial infarction","volume":"44","author":"Fujimori","year":"2004","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.tox.2021.153042_bib0080","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lfs.2016.01.047","article-title":"Therapeutic potential of endothelin inhibitors in canine hemangiosarcoma","volume":"159","author":"Fukumoto","year":"2016","journal-title":"Life Sci."},{"key":"10.1016\/j.tox.2021.153042_bib0085","doi-asserted-by":"crossref","first-page":"8671","DOI":"10.1200\/JCO.2004.00.5686","article-title":"Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089","volume":"23","author":"Haller","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.tox.2021.153042_bib0090","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/JXX.0000000000000104","article-title":"Review of evidence for bosentan therapy for treatment of Eisenmenger syndrome","volume":"31","author":"Hartwig","year":"2019","journal-title":"J. Am. Assoc. Nurse Pract."},{"key":"10.1016\/j.tox.2021.153042_bib0095","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejphar.2018.10.033","article-title":"Cardioprotection and improvement in endothelial-dependent vasodilation during late-phase of whole body hypoxic preconditioning in spontaneously hypertensive rats via VEGF and endothelin-1","volume":"842","author":"Hong","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tox.2021.153042_bib0100","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2018.04.005","article-title":"Sitagliptin prevents isoproterenol-induced myocardial infarction in rats by modulating nitric oxide synthase enzymes","volume":"829","author":"Ibrahim","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.tox.2021.153042_bib0105","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/FJC.0000000000000296","article-title":"Comparison of macitentan and bosentan on right ventricular remodeling in a rat model of non-vasoreactive pulmonary hypertension","volume":"66","author":"Iglarz","year":"2015","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.tox.2021.153042_bib0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11010-006-1926-1","article-title":"Improvement in cardiac function of diabetic rats by bosentan is not associated with changes in the activation of PKC isoforms","volume":"282","author":"Jiang","year":"2006","journal-title":"Mol. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.tox.2021.153042_bib0115","first-page":"399","article-title":"Fluoropyrimidine-associated cardiotoxicity","volume":"37","author":"Kanduri","year":"2019","journal-title":"Cardiol. Clin."},{"issue":"6","key":"10.1016\/j.tox.2021.153042_bib0120","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1167\/iovs.14-14193","article-title":"The ocular endothelin system: a novel target for the treatment of endotoxin-induced uveitis with bosentan","volume":"55","author":"Keles","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"7\u20138","key":"10.1016\/j.tox.2021.153042_bib0125","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1345\/aph.1C256","article-title":"Bosentan for the treatment of pulmonary arterial hypertension","volume":"37","author":"Kenyon","year":"2003","journal-title":"Ann. Pharmacother."},{"issue":"10","key":"10.1016\/j.tox.2021.153042_bib0130","doi-asserted-by":"crossref","first-page":"e0075","DOI":"10.1097\/MD.0000000000010075","article-title":"The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: a systematic review and meta-analysis","volume":"97","author":"Kuang","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.tox.2021.153042_bib0135","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/07357900701522588","article-title":"Endothelin receptor antagonists in cancer therapy","volume":"25","author":"Lalich","year":"2007","journal-title":"Cancer Invest."},{"issue":"3","key":"10.1016\/j.tox.2021.153042_bib0140","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.toxlet.2014.03.018","article-title":"A mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectives","volume":"227","author":"Lamberti","year":"2014","journal-title":"Toxicol. Lett."},{"issue":"5","key":"10.1016\/j.tox.2021.153042_bib0145","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0093-7754(03)00353-1","article-title":"Endothelin receptor antagonists in the treatment of prostate cancer","volume":"30","author":"Lassiter","year":"2003","journal-title":"Semin. Oncol."},{"issue":"6","key":"10.1016\/j.tox.2021.153042_bib0150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11912-016-0521-1","article-title":"Fluoropyrimidine-induced cardiotoxicity: manifestations, mechanisms, and management","volume":"18","author":"Layoun","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.tox.2021.153042_bib0155","first-page":"206765","article-title":"Takotsubo cardiomyopathy and 5-Fluorouracil: getting to the heart of the matter","volume":"2013","author":"Lim","year":"2013","journal-title":"Case Rep. Oncol. Med."},{"key":"10.1016\/j.tox.2021.153042_bib0160","doi-asserted-by":"crossref","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.tox.2021.153042_bib0165","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/jcb.29556","article-title":"Ginsenoside Rg1 attenuates cardiomyocyte apoptosis and inflammation via the TLR4\/NF-kB\/NLRP3 pathway","volume":"121","author":"Luo","year":"2020","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.tox.2021.153042_bib0170","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0003-2697(78)90342-1","article-title":"Determination of malonaldehyde precursor in tissues by thiobarbituric acid test","volume":"86","author":"Mihara","year":"1978","journal-title":"Anal. Biochem."},{"issue":"2","key":"10.1016\/j.tox.2021.153042_bib0175","first-page":"208","article-title":"Evaluation of cardioprotective activity of Lepidium sativum seed powder in albino rats treated with 5-fluorouracil","volume":"5","author":"Mohamed","year":"2016","journal-title":"Beni-suef Univ. J. Basic Appl. Sci."},{"issue":"1","key":"10.1016\/j.tox.2021.153042_bib0180","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0304-4165(79)90289-7","article-title":"Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver","volume":"582","author":"Moron","year":"1979","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.tox.2021.153042_bib0185","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0002-9343(88)80268-7","article-title":"Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers","volume":"85","author":"Oleksowicz","year":"1988","journal-title":"Am. J. Med."},{"key":"10.1016\/j.tox.2021.153042_bib0190","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2174\/138161207780487566","article-title":"Restoring the dysfunctional endothelium","volume":"13","author":"Osto","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.tox.2021.153042_bib0195","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdt479","article-title":"Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines","volume":"25","author":"Ransom","year":"2014","journal-title":"Ann. Oncol."},{"issue":"June 29","key":"10.1016\/j.tox.2021.153042_bib0200","article-title":"The IL-6\/STAT signaling pathway and PPAR\u03b1 are involved in mediating the dose-dependent cardioprotective effects of fenofibrate in 5-fluorouracil-Induced cardiotoxicity","author":"Refaie","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.tox.2021.153042_bib0205","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/MCA.0000000000000347","article-title":"Coronary endothelial function testing provides superior discrimination compared with standard clinical risk scoring in prediction of cardiovascular events","volume":"27","author":"Reriani","year":"2016","journal-title":"Coron. Artery Dis."},{"key":"10.1016\/j.tox.2021.153042_bib0210","series-title":"Nebivolol - Pharmacological Aspects: a Review","year":"2011"},{"key":"10.1016\/j.tox.2021.153042_bib0215","first-page":"531","article-title":"Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series","volume":"27","author":"Saif","year":"2013","journal-title":"In Vivo"},{"key":"10.1016\/j.tox.2021.153042_bib0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: a review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"2","key":"10.1016\/j.tox.2021.153042_bib0225","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bcp.2015.01.014","article-title":"Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy","volume":"94","author":"Schwebe","year":"2015","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.tox.2021.153042_bib0230","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1742-7843.2006.pto_405.x","article-title":"Cardioprotective effects of bosentan, a mixed endothelin type A and B receptor antagonist, during myocardial ischaemia and reperfusion in rats","volume":"98","author":"Singh","year":"2006","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"9","key":"10.1016\/j.tox.2021.153042_bib0235","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092885","article-title":"Management of cardiac toxicity induced by chemotherapy","volume":"9","author":"Trapani","year":"2020","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.tox.2021.153042_bib0240","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/0003319716637516","article-title":"Usefulness of heart-type fatty acid-binding protein and myocardial performance index for early detection of 5-fluorouracil cardiotoxicity","volume":"68","author":"Turan","year":"2017","journal-title":"Angiology"},{"issue":"8","key":"10.1016\/j.tox.2021.153042_bib0245","first-page":"95","article-title":"Bosentan use in pulmonary arterial hypertension: Russian and foreign experience","volume":"89","author":"Valieva","year":"2017","journal-title":"Ter. Arkh."},{"issue":"18","key":"10.1016\/j.tox.2021.153042_bib0250","doi-asserted-by":"crossref","first-page":"10677","DOI":"10.1111\/jcmm.15688","article-title":"Danshen (Salvia miltiorrhiza) restricts MD2\/TLR4-MyD88 complex formation and signalling in acute myocardial infarction-induced heart failure","volume":"24","author":"Wang","year":"2020","journal-title":"J. Cell. Mol. Med."},{"issue":"5","key":"10.1016\/j.tox.2021.153042_bib0255","doi-asserted-by":"crossref","first-page":"e2234","DOI":"10.1038\/cddis.2016.140","article-title":"The emerging role of Toll-like receptor 4 in myocardial inflammation","volume":"7","author":"Yang","year":"2016","journal-title":"Cell Death Dis."}],"container-title":["Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X21003644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X21003644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T23:50:28Z","timestamp":1759535428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300483X21003644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":51,"alternative-id":["S0300483X21003644"],"URL":"https:\/\/doi.org\/10.1016\/j.tox.2021.153042","relation":{},"ISSN":["0300-483X"],"issn-type":[{"value":"0300-483X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardioprotective effects of bosentan in 5-fluorouracil-induced cardiotoxicity","name":"articletitle","label":"Article Title"},{"value":"Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tox.2021.153042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"153042"}}